Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Other Working Capital Changes (2016 - 2025)

Adma Biologics' Other Working Capital Changes history spans 13 years, with the latest figure at $547000.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 136.08% year-over-year to $547000.0; the TTM value through Dec 2025 reached $1.5 million, down 43.41%, while the annual FY2025 figure was $1.5 million, 43.41% down from the prior year.
  • Other Working Capital Changes reached $547000.0 in Q4 2025 per ADMA's latest filing, up from -$1.1 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $4.0 million in Q3 2024 to a low of -$1.6 million in Q1 2024.
  • Average Other Working Capital Changes over 5 years is $325400.0, with a median of -$64095.0 recorded in 2021.
  • The largest YoY upside for Other Working Capital Changes was 3690.18% in 2024 against a maximum downside of 767.84% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$1.5 million in 2021, then surged by 81.76% to -$277238.0 in 2022, then surged by 181.88% to $227000.0 in 2023, then plummeted by 767.84% to -$1.5 million in 2024, then soared by 136.08% to $547000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Other Working Capital Changes are $547000.0 (Q4 2025), -$1.1 million (Q3 2025), and -$501000.0 (Q2 2025).